A2A TACC3 Program Clinical Progress in Womens Cancers

May 27, 2025 - A2A Pharmaceuticals a clinical stage oncology company with the lead asset AO-252, a PPI inhibitor of TACC3 which is a 1st in Class/1st in human program , today announced progress in Phase 1, dose escalation for ovarian, triple negative and endometrial cancer patients.

Significant (22% average over approximately 2 months) tumor reduction in 67% of the 4b (BID) cohort patients was observed. This is at 160mg ,which is less than 1/3 of what we project to be to be the maximum tolerated dose as predicted by a very wide therapeutic index in pre-clinical studies. With no dose limiting toxicity and benign safety profile observed thus far, we are now at 240mg.

We plan to initiate dose expansion and add prostate, gastric, sarcoma and patients with brain metastasis this summer.

While our primary focus is on mono-therapy, where we saw preclinical regressions in the above indications with PDX and organoid validation, we have seen strong synergy with chemotherapy and targeted therapies like Enehrtu and anti Pd-1 and Trop2 ADC's in preclinical models as well